Oruka Therapeutics (ORKA) Shareholder's Equity Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.16% |
| Dec 31, 2025 | 58.94% |
| Sep 30, 2025 | 57.36% |
| Jun 30, 2025 | 101.66% |
| Mar 31, 2025 | 125.13% |
| Dec 31, 2024 | 118.87% |
| Sep 30, 2024 | 107.98% |
| Jun 30, 2024 | -38.81% |
| Mar 31, 2024 | -24.28% |
| Dec 31, 2023 | 43.75% |
| Sep 30, 2023 | 38.45% |
| Jun 30, 2023 | 34.25% |
| Mar 31, 2023 | 29.67% |
| Dec 31, 2022 | 32.32% |
| Sep 30, 2022 | 24.38% |
| Jun 30, 2022 | 24.98% |
| Mar 31, 2022 | 21.59% |
| Dec 31, 2021 | 18.12% |
| Sep 30, 2021 | 16.41% |
| Jun 30, 2021 | 14.66% |
| Mar 31, 2021 | 13.77% |
| Dec 31, 2020 | 4.09% |
| Sep 30, 2020 | 4.19% |
| Jun 30, 2020 | -25.11% |
| Mar 31, 2020 | -12.26% |
| Dec 31, 2019 | -12.39% |
| Sep 30, 2019 | -12.54% |
| Jun 30, 2019 | -13.81% |
| Mar 31, 2019 | -19.42% |
| Dec 31, 2018 | -17.29% |
| Sep 30, 2018 | -16.48% |
| Jun 30, 2018 | -14.79% |
| Mar 31, 2018 | 27.27% |
| Dec 31, 2017 | 28.73% |
| Sep 30, 2017 | 35.21% |
| Jun 30, 2017 | 35.01% |
| Mar 31, 2017 | 32.86% |
| Dec 31, 2016 | 31.09% |
| Sep 30, 2016 | 35.81% |
| Jun 30, 2016 | 32.57% |
| Dec 31, 2015 | 41.25% |